肝性脑病发病机制中的多器官交互作用

赵子昕; 祝叶青; 叶存心; 宋卓芫; 宋冬

doi:10.12449/JCH260533

肝性脑病发病机制中的多器官交互作用

DOI: 10.12449/JCH260533

南京医科大学康达学院，江苏连云港 222000

基金项目:

2022年度江苏高校哲学社会科学研究一般项目 (2022SJYB1865);

南京医科大学2023年度教育研究课题一般项目 (2023ZC104);

南京医科大学康达学院第二期“科研人才培养计划” (KD2022KYRC012)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：赵子昕负责拟定文章思路，并起草和修改文章的关键内容；祝叶青负责搜集参考文献；叶存心负责图片制作；宋卓芫负责文章格式修改与投稿；宋冬负责指导文章撰写以及最终定稿。

详细信息

通信作者:
宋冬， songdong@njmu.edu.cn （ORCID： 0009-0002-2432-2779）

计量
- 文章访问数: 10
- HTML全文浏览量: 4
- PDF下载量: 0
- 被引次数: 0
出版历程
- 收稿日期: 2025-10-14
- 录用日期: 2025-10-27
- 出版日期: 2026-05-20

Multiorgan crosstalk in the pathogenesis of hepatic encephalopathy

Kangda College，Nanjing Medical University，Lianyungang，Jiangsu 222000，China

Research funding:

2022 General Project of Philosophy and Social Science Research in Jiangsu Universities (2022SJYB1865);

2023 General Project of Education Research Topic of Nanjing Medical University (2023ZC104);

The Second Phase of ‘Scientific Research Talent Training Plan’ at Kangda College of Nanjing Medical University (KD2022KYRC012)

More Information

Corresponding author: SONG Dong， songdong@njmu.edu.cn （ORCID： 0009-0002-2432-2779）

摘要

摘要: 肝性脑病是肝硬化等终末期肝病常见且严重的并发症，其本质是由于急性或慢性肝功能严重障碍或门体分流引起的以代谢紊乱为基础的神经精神异常综合征。临床实践中，肝性脑病的发作与血氨水平并非完全线性相关，常由肝外因素诱发，提示其发病机制中存在多器官间的复杂交互。本文基于氨中毒、炎症、神经递质失衡及氧化/硝化应激4种主要发病机制，系统阐述肝性脑病中的多器官交互作用机制，并结合肌少症、糖尿病等新兴风险因素展开讨论，旨在为深入探究肝性脑病的病理生理机制及未来临床诊疗策略的制定提供新的理论依据。
- 肝性脑病 /
- 病理过程 /
- 多器官交互
Abstract: Hepatic encephalopathy is a common and serious complication of end-stage liver diseases such as liver cirrhosis， and it is basically a neuropsychiatric syndrome resulting from metabolic disorders caused by severe acute or chronic liver dysfunction or portosystemic shunt. In clinical practice， the onset of hepatic encephalopathy does not completely correlate linearly with the level of blood ammonia and is often triggered by extrahepatic factors， suggesting the presence of complex multiorgan crosstalk in the pathogenesis of hepatic encephalopathy. Based on the four main pathogeneses of ammonia toxicity， inflammation， neurotransmitter imbalance， and oxidative/nitrosative stress， this article systematically elaborates on the mechanism of multiorgan crosstalk in hepatic encephalopathy and discusses the emerging risk factors such as sarcopenia and diabetes mellitus， in order to provide a novel theoretical framework for deepening the understanding of the pathophysiological mechanisms of hepatic encephalopathy and formulating clinical diagnosis and treatment strategies in the future.
- Hepatic Encephalopathy /
- Pathologic Processes /
- Multiorgan Crosstalk

HTML全文

注： TNF-α，肿瘤坏死因子α；IL-6，白细胞介素6；ROS，活性氧；NADPH，还原型烟酰胺腺嘌呤二核苷酸磷酸。

图 1 肝性脑病中的多器官交互作用机制

Figure 1. The mechanism of multiorgan crosstalk in hepatic encephalopathy

下载: 全尺寸图片幻灯片

参考文献(32)

[1]	WEISSENBORN K. Hepatic encephalopathy: Definition, clinical grading and diagnostic principles[J]. Drugs, 2019, 79( Suppl 1): 5- 9. DOI: 10.1007/s40265-018-1018-z.
[2]	FIATI KENSTON SS, SONG X, LI Z, et al. Mechanistic insight, diagnosis, and treatment of ammonia-induced hepatic encephalopathy[J]. J Gastroenterol Hepatol, 2019, 34( 1): 31- 39. DOI: 10.1111/jgh.14408.
[3]	ELSAID MI, RUSTGI VK. Epidemiology of hepatic encephalopathy[J]. Clin Liver Dis, 2020, 24( 2): 157- 174. DOI: 10.1016/j.cld.2020.01.001.
[4]	LABENZ C, NAGEL M, KREMER WM, et al. Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2020, 52( 3): 527- 536. DOI: 10.1111/apt.15915.
[5]	RUDLER M, WEISS N, BOUZBIB C, et al. Diagnosis and management of hepatic encephalopathy[J]. Clin Liver Dis, 2021, 25( 2): 393- 417. DOI: 10.1016/j.cld.2021.01.008.
[6]	DENG MJ, CAI JR, SHI PM, et al. Pathogenesis and treatment of hepatic encephalopathy: Research progress[J]. Acad J Nav Med Univ, 2025, 46( 6): 784- 789. DOI: 10.16781/j.CN31-2187/R.20240719. 邓明杰, 蔡加荣, 时培美, 等. 肝性脑病发病机制及治疗研究进展[J]. 海军军医大学学报, 2025, 46( 6): 784- 789. DOI: 10.16781/j.CN31-2187/R.20240719.
[7]	SABOO K, SHAMSADDINI A, IYER MV, et al. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy[J]. J Hepatol, 2021, 74( 1): 80- 88. DOI: 10.1016/j.jhep.2020.06.046.
[8]	HÄUSSINGER D, DHIMAN RK, FELIPO V, et al. Hepatic encephalopathy[J]. Nat Rev Dis Primers, 2022, 8: 43. DOI: 10.1038/s41572-022-00366-6.
[9]	TRANAH TH, BALLESTER MP, CARBONELL-ASINS JA, et al. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis[J]. J Hepatol, 2022, 77( 6): 1554- 1563. DOI: 10.1016/j.jhep.2022.07.014.
[10]	HARRIS KB, GONZALEZ HC, GORDON SC. The health care burden of hepatic encephalopathy[J]. Clin Liver Dis, 2024, 28( 2): 265- 272. DOI: 10.1016/j.cld.2024.01.009.
[11]	MISHRA AK, DHIMAN RK. Hepatic encephalopathy in cirrhosis: Therapies and developments[J]. Metab Brain Dis, 2025, 40( 5): 198. DOI: 10.1007/s11011-025-01598-7.
[12]	THOMSEN KL, SØRENSEN M, KJÆRGAARD K, et al. Cerebral aspects of portal hypertension: Hepatic encephalopathy[J]. Clin Liver Dis, 2024, 28( 3): 541- 554. DOI: 10.1016/j.cld.2024.03.008.
[13]	KIBBLE H, SHAWCROSS DL. The assessment and management of cirrhotic patients with encephalopathy[J]. United European Gastroenterol J, 2024, 12( 2): 187- 193. DOI: 10.1002/ueg2.12530.
[14]	SIMICIC D, CUDALBU C, PIERZCHALA K. Overview of oxidative stress findings in hepatic encephalopathy: From cellular and ammonium-based animal models to human data[J]. Anal Biochem, 2022, 654: 114795. DOI: 10.1016/j.ab.2022.114795.
[15]	YANG S, ZHANG L, JIN Q, et al. Meld-sarcopenia score and skeletal muscle density predicts short-term readmission of patients with hepatic encephalopathy[J]. Eur J Radiol, 2023, 169: 111178. DOI: 10.1016/j.ejrad.2023.111178.
[16]	NARDELLI S, RIGGIO O, MARRA F, et al. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis[J]. J Hepatol, 2024, 80( 4): 596- 602. DOI: 10.1016/j.jhep.2023.11.033.
[17]	SEN BK, PAN K, CHAKRAVARTY A. Hepatic encephalopathy: Current thoughts on pathophysiology and management[J]. Curr Neurol Neurosci Rep, 2025, 25( 1): 28. DOI: 10.1007/s11910-025-01415-9.
[18]	KOSENKO E, TIKHONOVA L, ALILOVA G, et al. Is NMDA-receptor-mediated oxidative stress in mitochondria of peripheral tissues the essential factor in the pathogenesis of hepatic encephalopathy?[J]. J Clin Med, 2022, 11( 3): 827. DOI: 10.3390/jcm11030827.
[19]	SANTOS RPC, de BRITO TOSCANO EC, RACHID MA. Anti-inflammatory strategies for hepatic encephalopathy: Preclinical studies[J]. Arq Neuropsiquiatr, 2023, 81( 7): 656- 669. DOI: 10.1055/s-0043-1767819.
[20]	TAHERIAN M, NORENBERG MD, PANICKAR KS, et al. Additive effect of resveratrol on astrocyte swelling post-exposure to ammonia, ischemia and trauma in vitro[J]. Neurochem Res, 2020, 45( 5): 1156- 1167. DOI: 10.1007/s11064-020-02997-1.
[21]	CLAEYS W, van HOECKE L, LERNOUT H, et al. Experimental hepatic encephalopathy causes early but sustained glial transcriptional changes[J]. J Neuroinflammation, 2023, 20( 1): 130. DOI: 10.1186/s12974-023-02814-w.
[22]	BAJAJ JS, POMPILI E, CARACENI P. The burden of hepatic encephalopathy and the use of albumin as a potential treatment[J]. Ann Hepatol, 2025, 30( 1): 101751. DOI: 10.1016/j.aohep.2024.101751.
[23]	BLOOM PP. A new gut-brain therapeutic target for hepatic encephalopathy[J]. Nat Med, 2025, 31( 2): 386- 387. DOI: 10.1038/s41591-024-03467-9.
[24]	HÄUSSINGER D, BUTZ M, SCHNITZLER A, et al. Pathomechanisms in hepatic encephalopathy[J]. Biol Chem, 2021, 402( 9): 1087- 1102. DOI: 10.1515/hsz-2021-0168.
[25]	GÖRG B, KARABABA A, SCHÜTZ E, et al. O-GlcNAcylation-dependent upregulation of HO1 triggers ammonia-induced oxidative stress and senescence in hepatic encephalopathy[J]. J Hepatol, 2019, 71( 5): 930- 941. DOI: 10.1016/j.jhep.2019.06.020.
[26]	ZIELIŃSKA M, POPEK M, ALBRECHT J. Neuroglia in hepatic encephalopathy[J]. Handb Clin Neurol, 2025, 210: 191- 212. DOI: 10.1016/B978-0-443-19102-2.00011-9.
[27]	ENGELMANN C. Rethinking hepatic encephalopathy: Gut microbes, neurotoxins and the therapeutic horizon[J]. J Hepatol, 2025, 83( 2): 601- 603. DOI: 10.1016/j.jhep.2025.04.036.
[28]	ZENG SL, LYU C, XIAO WS, et al. Mechanism of action of intestinal flora in hepatic encephalopathy and related treatment methods[J]. J Clin Hepatol, 2020, 36( 10): 2375- 2379. DOI: 10.3969/j.issn.1001-5256.2020.10.047. 曾胜澜, 吕超, 肖伟松, 等. 肝性脑病中肠道菌群的作用机制及治疗方法[J]. 临床肝胆病杂志, 2020, 36( 10): 2375- 2379. DOI: 10.3969/j.issn.1001-5256.2020.10.047.
[29]	GALLEGO-DURÁN R, HADJIHAMBI A, AMPUERO J, et al. Ammonia-induced stress response in liver disease progression and hepatic encephalopathy[J]. Nat Rev Gastroenterol Hepatol, 2024, 21( 11): 774- 791. DOI: 10.1038/s41575-024-00970-9.
[30]	ROSE CF, AMODIO P, BAJAJ JS, et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy[J]. J Hepatol, 2020, 73( 6): 1526- 1547. DOI: 10.1016/j.jhep.2020.07.013.
[31]	LE GUENNEC L, MOURI S, THABUT D, et al. Blood-brain barrier dysfunction in hepatic encephalopathy: Pathophysiology, diagnostic assessment and therapeutic perspectives[J]. Metab Brain Dis, 2025, 40( 5): 223. DOI: 10.1007/s11011-025-01645-3.
[32]	HE XL, HU MY, XU Y, et al. The gut-brain axis underlying hepatic encephalopathy in liver cirrhosis[J]. Nat Med, 2025, 31( 2): 627- 638. DOI: 10.1038/s41591-024-03405-9.